Granulomatosis With Polyangiitis Linked to Altered Nasal Microbial Composition

Granulomatosis With Polyangiitis Linked to Altered Nasal Microbial Composition

Granulomatosis with polyangiitis was associated with an altered nasal microbial composition at both the bacterial and the fungal levels.

Examining Risk for Severe Infection in Rituximab-Treated AAV

Examining Risk for Severe Infection in Rituximab-Treated AAV

Researchers observed severe infections in one-quarter of patients with AAV receiving rituximab.

Renal Transplantation Linked to Improved Survival for ESRD Due to Granulomatosis With Polyangiitis

Renal Transplantation Linked to Improved Survival for ESRD Due to Granulomatosis With Polyangiitis

Renal transplantation is associated with a significant decrease in mortality among patients with end-stage renal disease attributed to granulomatosis with polyangiitis.

Individually Tailored vs Fixed-Schedule Rituximab Regimens in ANCA-Associated Vasculitis

Individually Tailored vs Fixed-Schedule Rituximab Regimens in ANCA-Associated Vasculitis

Results of the MAINRITSAN2 trial show that ANCA-associated vasculitides relapse rates did not differ significantly among patients treated with individually tailored vs fixed-schedule rituximab infusion regimens.

Takayasu Arteritis: Efficacy and Safety of Tocilizumab vs Placebo

Takayasu Arteritis: Efficacy and Safety of Tocilizumab vs Placebo

Tocilizumab therapy improves time to relapse in Takayasu arteritis with a favorable safety and tolerability profile.

Large Vessel Vasculitis Imaging: Recommendations for Clinical Practice

Large Vessel Vasculitis Imaging: Recommendations for Clinical Practice

EULAR has released 12 evidence-based recommendations for the use of imaging in the diagnosis and monitoring of large vessel vasculitis, including giant cell arteritis and Takayasu arteritis.

First Treatment for Eosinophilic Granulomatosis With Polyangiitis Approved by FDA

First Treatment for Eosinophilic Granulomatosis With Polyangiitis Approved by FDA

The FDA has expanded the approval of mepolizumab for treating eosinophilic granulomatosis with polyangiitis, which causes vasculitis.

Azathioprine With Glucocorticoids in Nonsevere Systemic Necrotizing Vasculitides

Azathioprine With Glucocorticoids in Nonsevere Systemic Necrotizing Vasculitides

Adding azathioprine to glucocorticoids has no significant benefit for patients with nonsevere systemic necrotizing vasculitides.

Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Biomarkers Identified

Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Biomarkers Identified

Several circulating biomarkers for antineutrophil cytoplasmic antibody-associated vasculitis disease activity and organ involvement were identified using targeted serum proteomics.

Pulmonary Involvement in Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis

Pulmonary Involvement in Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis

Central airway disease and a nodular pattern of pulmonary involvement occurred significantly more often in PR3-ANCA-positive patients than in MPO-ANCA-positive patients.

Sign Up for Free e-newsletters